Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 27:42:e2023162.
doi: 10.1590/1984-0462/2024/42/2023162. eCollection 2024.

Bronchodilator response assessment through impulse oscillometry system and spirometry in children and adolescents with cystic fibrosis

Tayná Castilho  1 , José Dirceu Ribeiro  1 , Renata Maba Gonçalves Wamosy  2 , Juliana Cardoso  2 , Gabriela Castilhos Ducati  2 , Camila Isabel Santos Schivinski  2
Affiliations

Bronchodilator response assessment through impulse oscillometry system and spirometry in children and adolescents with cystic fibrosis

Tayná Castilho et al. Rev Paul Pediatr. .

Abstract
in English, Portuguese

Objective: To investigate the effect of bronchodilator on the respiratory mechanics and pulmonary function of children and adolescents with cystic fibrosis.

Methods: Cross-sectional study on clinically stable children and adolescents with cystic fibrosis aged from six to 15 years. Participants underwent impulse oscillometry and spirometry evaluations before and 15 minutes after bronchodilator inhalation. The Kolmogorov-Smirnov test was applied to verify the sample distribution, and the Student's t-test and Wilcoxon test were used to compare the data before and after bronchodilator inhalation.

Results: The study included 54 individuals with a mean age of 9.7±2.8 years. The analysis showed a statistically significant improvement in impulse oscillometry and spirometry parameters after bronchodilator inhalation. However, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) recommendations (2020 and 2021), this improvement was not sufficient to classify it as a bronchodilator response.

Conclusions: The use of bronchodilator medication improved respiratory mechanics and pulmonary function parameters of children and adolescents with cystic fibrosis; however, most patients did not show bronchodilator response according to ATS/ERS recommendations.

Objetivo:: Investigar o efeito do broncodilatador na mecânica respiratória e função pulmonar de crianças e adolescentes com fibrose cística.

Métodos:: Estudo transversal em crianças e adolescentes com fibrose cística clinicamente estáveis, com idade entre seis e 15 anos. Os participantes realizaram avaliações por meio do sistema de oscilometria de impulso e espirometria antes e 15 minutos depois da inalação de broncodilatador. Foi aplicado o teste Kolmogorov-Smirnov para verificar a distribuição da amostra. Para comparar os dados antes e depois do broncodilatador foram utilizados os testes t de Student e Wilcoxon.

Resultados:: Participaram do estudo 54 indivíduos com média de idade de 9,7±2,8 anos. Houve melhora estatisticamente significativa nos parâmetros do oscilometria de impulso e espirometria após a inalação com broncodilatador. No entanto, de acordo com recomendações da American Thoracic Society (ATS) e European Respiratory Society (ERS) (2020 and 2021), essa melhora não foi suficiente para classificar como reposta broncodilatadora.

Conclusões:: O uso de medicamento broncodilatador melhorou a mecânica respiratória e função pulmonar de crianças e adolescentes com fibrose cística, no entanto a maioria da amostra não apresentou resposta ao broncodilatador de acordo com as recomendações da ATS/ERS.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests

The authors declare there is no conflict of interests.

Figures

Figure 1
Figure 1. Comparison of spirometric parameters between pre- and post-BD.
Figure 2
Figure 2. Comparison of oscillometric parameters between pre- and post-BD.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64:450–504. doi: 10.1124/pr.111.004580. - DOI - PubMed
    1. Cazzola M, Rogliani P, Calzetta L, Matera MG. Bronchodilators in subjects with asthma-related comorbidities. Respir Med. 2019;151:43–48. doi: 10.1016/j.rmed.2019.04.001. - DOI - PubMed
    1. Pizzichini MM, Carvalho-Pinto RM, Cançado JE, Rubin AS, Cerci A, Neto, Cardoso AP, et al. Recomendações para o manejo da asma da Sociedade Brasileira de Pneumologia e Tisiologia – 2020. J Bras Pneumol. 2020;46:e20190307. doi: 10.1590/1806-3713/e20190307. - DOI - PMC - PubMed
    1. Smith S, Edwards CT. Long-acting inhaled bronchodilators for cystic fibrosis. Paediatr Respir Rev. 2018;28:31–32. doi: 10.1016/j.prrv.2018.04.002. - DOI - PubMed
    1. Barry PJ, Flume PA. Bronchodilators in cystic fibrosis: a critical analysis. Expert Rev Respir Med. 2017;11:13–20. doi: 10.1080/17476348.2017.1246358. - DOI - PubMed

Substances